![Trifluridine/tipiracil hydrochloride mixture (TAS-102) | Nucleoside Antitumour Agent | MedChemExpress Trifluridine/tipiracil hydrochloride mixture (TAS-102) | Nucleoside Antitumour Agent | MedChemExpress](https://file.medchemexpress.com/product_pic/hy-16478.gif)
Trifluridine/tipiracil hydrochloride mixture (TAS-102) | Nucleoside Antitumour Agent | MedChemExpress
![TAS-102 (Trifluridine-tipiracil hydrochloride mixture) | Nucleoside Antimetabolite/Analog Inhibitor | Cas# 733030-01-8 - GlpBio TAS-102 (Trifluridine-tipiracil hydrochloride mixture) | Nucleoside Antimetabolite/Analog Inhibitor | Cas# 733030-01-8 - GlpBio](https://www.glpbio.com/media/struct/GC1/GC19348.png)
TAS-102 (Trifluridine-tipiracil hydrochloride mixture) | Nucleoside Antimetabolite/Analog Inhibitor | Cas# 733030-01-8 - GlpBio
Orientations visant l'application des mesures de santé publique non médicales par les populations en situation de vulnéra
![Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status | SpringerLink Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status | SpringerLink](https://media.springernature.com/w136h75/springer-static/image/art%3A10.1186%2Fs12885-019-6475-6/MediaObjects/12885_2019_6475_Fig1_HTML.png)
Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status | SpringerLink
![Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status | SpringerLink Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12094-019-02154-3/MediaObjects/12094_2019_2154_Fig2_HTML.png)
Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status | SpringerLink
![Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status | SpringerLink Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status | SpringerLink](https://media.springernature.com/w136h75/springer-static/image/art%3A10.1007%2Fs10147-020-01794-8/MediaObjects/10147_2020_1794_Fig1_HTML.png)